Inactive

The objective of this acquisition is to obtain cloud platform services to support data collection, dissemination, analysis, integration, reporting, and management of the BGTC. The BGTC is part of the ... The objective of this acquisition is to obtain cloud platform services to support data collection, dissemination, analysis, integration, reporting, and management of the BGTC. The BGTC is part of the Accelerating Medicines Partnership (AMP) program, a public–private partnership among NIH, the U.S. Food and Drug Administration (FDA), multiple pharmaceutical and life sciences companies, and nonprofit and other organizations. The AMP program, which is managed by the Foundation for the NIH (FNIH), aims to improve current models for developing diagnostics and therapies. NCATS is the lead NIH IC for BGTC, one of several NCATS-led programs aligned with the NCATS’ mission to re-engineer the translational research process so new treatments and cures for diseases can be delivered to patients faster. The BGTC is establishing platforms and standards to speed the development and delivery of customized or “bespoke” gene therapies (GT) that could treat millions of people affected by rare diseases, including diseases too rare to be of commercial interest.